Sentences with phrase «cell and gene medicine»

His laboratory (The Laboratory for Cell and Gene Medicine) specializes in the development of manufacturing processes and QC assays and provides cGMP compliant clinical materials production and regulatory support activities for investigational cell products.

Baldrick's Foundation Pediatric Cancer Dream Team and Associate Director, Stanford Cancer Institute; Co-medical Director, Standford Laboratory for Cell and Gene Medicine Dr. Gabriel Otte, Co-founder and CEO, Freenome Inc..

Improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data driven design

Not exact matches

New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.

Gene Yeo, a professor of cellular and molecular medicine at UCSD, led the research and showed he could target RNA in living cells, a first step toward treating diseases like muscular dystrophy and neurodegeneration.

«It was kind of fun being at a medical school and known as the weird guy who worked with dogs,» says Modiano, who is now a professor of comparative oncology at the University of Minnesota College of Veterinary Medicine and the Masonic Cancer Center, where his research focuses on immunology, cancer cell biology, cancer genetics, and applications of gene therapy.

«The gene has been cloned, and we know it interferes with the production of toxic amyloid fragments,» says Ralph Nixon, a professor of psychiatry and cell biology at New York University School of Medicine and a past chair of the Medical and Scientific Advisory Council of the Alzheimer's Association.

Priscilla N. Kelly Associate Editor Education: B.Sc., University of Western Australia; Ph.D., University of Melbourne Areas of responsibility: Preclinical development, translational medicine, cancer immunotherapy, drug discovery, clinical trials, gene and cell therapy E-Mail: [email protected]

In a 2006 study published in Cell, Vidal and Huda Zoghbi, a neurobiologist at Baylor College of Medicine in Houston, Texas, teamed up to show previously unsuspected interactions among the proteins produced by mutated genes in several of the movement disorders known as ataxias.

Researchers at the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital and Houston Methodist have developed an alternative treatment in which virus - specific cells protect patients against severe, drug - resistant viral infections.

«In our experiments, our nanoparticles successfully delivered a test gene to brain cancer cells in mice, where it was then turned on,» says Jordan Green, Ph.D., an assistant professor of biomedical engineering and neurosurgery at the Johns Hopkins University School of Medicine.

At the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston, director Malcolm Brenner, a geneticist, says he has turned «AdV from poacher into gamekeeper.»

To better understand how HMGA1 affected the rodents» intestines, Resar and Lingling Xian, M.D., Ph.D., research associate at the Johns Hopkins University School of Medicine, and their colleagues examined the transgenic animals» intestinal cells to determine which ones were expressing this gene.

In a report that appears in PLOS BIOLOGY, Dr. Hugo Bellen and his colleagues at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital and BCM, and Dr. Chao Tong, at the Life Sciences Institute and Innovation Center for Cell Biology, Zhejiang University in Hangzhou, China, find that mutations of human homologs (genes that carry out similar functions) of cacophony and its partner straightjacket (Cacna1a and Cacna2d2 respectively) cause defects in autophagy in neurons.

One miRNA can target multiple genes, but their expression is often hijacked by cancer cells and disrupts multiple cancer - causing or tumor - suppressing pathways,» says Shuk - Mei Ho, PhD, director of the CCC and Jacob G. Schmidlapp Chair of Environmental Health and professor at the University of Cincinnati (UC) College of Medicine.

Of particular interest are the emerging techniques for genomics and proteomics, which allow profiles of gene expression and protein synthesis to be produced and comparisons to be made between normal and abnormal cells, as well as between cells before and after exposure to medicines or toxic chemicals.

In an effort to expand the number of cancer gene mutations that can be specifically targeted with personalized therapies, researchers at University of California San Diego School of Medicine and Moores Cancer Center looked for combinations of mutated genes and drugs that together kill cancer cells.

«Researchers ID cancer gene - drug combinations ripe for precision medicine: Yeast, human cells and bioinformatics help develop one - two punch approach to personalized cancer therapy.»

«If you look at a set of lung cancer patients, like we did in the paper, who develop brain metastases, they all have those two genes in their primary lung cancer,» said Sheila Singh, the study's supervisor, associate professor at the Michael G. DeGroote School of Medicine, scientist with the Stem Cell and Cancer Research Institute at McMaster University and neurosurgeon at McMaster Children's Hospital.

In a study led by Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research member Dr. Julian Martinez - Agosto, UCLA scientists have shown that two genes not previously known to be involved with the immune system play a crucial role in how progenitor stem cells are activated to fight infection.

Myc is a cancer - causing gene responsible for disrupting the normal 24 - hour internal rhythm and metabolic pathways in cancer cells, found a team led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

The team, which included members of the Health Science Center departments of medicine and biochemistry, investigators from the UT Southwestern Medical Center at Dallas and a group of collaborators from Austria, found that the gene that codes the enzyme D2 - hydroxyglutarate dehydrogenase (D2HGDH) is mutated in a subset of cancers called diffuse large B - cell lymphomas.

The studies on autophagy by Yoshinori Ohsumi, which earned him the Nobel Prize in Medicine in 2016, and the discovery of cell cycle regulatory genes for which Leland Hartwell, Timothy Hunt and Paul Nurse received the same award in 2001, including the research of Elizabeth Blackburn, Carol Greider and Jack Szostak on telomeres, telomerase and its protective effect on the chromosomes, were all made possible thanks to yeast.

Rivals such as Pfizer and Sanofi are also investing, and overall financing for gene and gene - modified cell therapies reached $ 1 billion in the first quarter of 2017, according to the Alliance of Regenerative Medicine.

«We found that MYSM1 creates access to proteins that enhance gene transcription and, ultimately, the maturation of natural killer cells themselves,» said Vijayalakshmi Nandakumar, a Ph.D. student at the Keck School of Medicine of USC and the study's first author.

Researchers from the University of Seville at the Andalusian Centre for Molecular Biology and Regenerative Medicine (Centro Andaluz de Biología Molecular y Medicina Regenerativa — Cabimer) have discovered that in eukaryotic cells the proximity of the genes to the nuclear pores, which are found in the nuclear membrane, contributes to maintaining the integrity of the genome.

In a series of studies this year, molecular geneticists at the University of Pittsburgh School of Medicine used a harmless virus to ferry new genes through the bloodstream, across blood vessel walls, and into almost every muscle cell in the bodies of hamsters bred to have human genetic diseases.

For the animal experiments, Savio Woo of the Center for Gene Therapy at Baylor College of Medicine in Houston and his colleagues first isolated liver cells from transgenic mice that produce the human protein a1 - antitrypsin in their livers, from where it is secreted into the blood.

But when physiologist H. Lee Sweeney of the University of Pennsylvania School of Medicine in Philadelphia and his colleagues put this faulty gene into embryonic quail muscle cells growing in lab dishes, the cells made a shortened version of the protein and incorporated it into their contractile machinery.

Liangxue Lai of the South China Institute for Stem Cell Biology and Regenerative Medicine in Guangzhou, China, and colleagues injected the gene editor into 35 beagle embryos.

«Molecular Medicine BioServices makes viruses for companies working on vaccines, gene, and cell therapies.

Polyploid cells, which carry additional copies of important tumor suppressor genes, are better protected and more resistant to cancer formation because they have these extra copies of the genome,» said Dr. Zhu, who is also an Assistant Professor of Pediatrics and Internal Medicine at UT Southwestern.

PHYSIOLOGY OR MEDICINE: Andrew Z. Fire of the Stanford University School of Medicine and Craig C. Mello of the University of Massachusetts Medical School, for their 1998 discovery of RNA interference, which regulates gene expression and helps defend cells against viruses.

«In a nutshell, what we found is that this gene has an effect on the frequency of these T follicular helper cells, which are important for the B cells and seem to be important for the disease,» says Dr. Kissler, who is also an assistant professor of medicine at Harvard Medical School.

To probe the link between gene and virus, neuroscientist HowardFederoff, of the University of Rochester School of Medicine, and his colleagues created mouse - cell cultures that expressed either theAPOE - e4 gene or another variant (APOE - e2 or APOE - e3), then infected the cells with herpes.

In today's issue of Science Translational Medicine, he and his colleagues present a more efficient way of finding such new uses for old drugs: by bringing together data on how diseases and drugs affect the activity of the roughly 30,000 genes in a human cell.

A physician with a longstanding interest in gene therapy, Dr. High was formerly a Professor at the Perelman School of Medicine of the University of Pennsylvania, an Investigator of the Howard Hughes Medical Institute, and the Founding Director of the Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia, a Center focused on developing novel cell and gene - based therapies for genetic disease.

Using a novel technique to genetically modify T cells for adoptive transfer, Carl June, Michael Kalos, David Porter, Bruce Levine, and colleagues at the University of Pennsylvania School of Medicine achieve clinical responses in patients with chronic lymphocytic leukemia, including two complete, durable (one year) clinical responses, accompanied by in vivo expansion and long - term functional persistence of gene - modified cells.

Now in experiments in mice reported this week in Cell Metabolism, researchers at Joslin Diabetes Centers have highlighted the ways in which the host's genes interact with the microbial genes to create such conditions, says senior author C. Ronald Kahn, M.D., Chief Academic Officer at Joslin Diabetes Center and Mary K. Iacocca Professor of Medicine at Harvard Medical School.

Therapeutic applications of CRISPR - Cas gene editing are being advanced with the goals of finding cures and treatments for a range of serious diseases, developing needed medicines for both household pets and production animals, and improving cell culture systems for bioproduction.

Data from this trial was previously presented at World Advanced Therapies and Regenerative Medicine (May 17 - 19,2017; London, UK) and the 20th Annual Meeting American Society of Gene and Cell Therapy (ASGCT, May 10 - 13, 2017; DC, USA).

The 2017 Annual Data Report details industry - specific statistics and trends from more than 850 leading cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide.

He is Member of the European Molecular Biology Organization (EMBO), has been President of the European Society of Gene and Cell Therapy (ESGCT), and has been appointed as expert on the «Human Gene Editing Study» of the US National Academies of Sciences and of Medicine, and on the Italian National Committee for Biosafety, Biotechnology and Life Sciences.

Supported by: Hear from leading expert Dr David DiGiusto, Stanford University School of Medicine, USA, as he shares his extensive experience in developing and optimizing manufacturing processes for cell and gene therapy products including:

In the second study, a team led by Shahin Rafii at Weill Cornell Medicine in New York City used adult mouse cells as their starting material, and then guided them through several steps — including exposure to some of the same gene - activating proteins — to create mature blood stem cells in a petri dish.

In a previous study, Shaw, an associate professor in Salk's Molecular and Cell Biology Laboratory and researcher in the Institute's new Helmsley Center for Genomic Medicine, demonstrated that cells lacking a normal copy of the LKB1 gene fail to activate AMPK in response to low energy levels.

«To everyone's jaw - dropping surprise, you needed only four genes,» says stem cell biologist David Scadden, director of the Center for Regenerative Medicine at the MGH and co-director of the Harvard Stem Cell Institcell biologist David Scadden, director of the Center for Regenerative Medicine at the MGH and co-director of the Harvard Stem Cell InstitCell Institute.

Don't miss the chance to make new contacts, connect with current clients, develop your cell therapy, regenerative medicine and gene therapy business.

Chris is on a number of national and international committees, working groups and initiatives related to the academic, clinical translation and commercialization of cell and gene therapies including; Founder and CEO of the London Regenerative Medicine Network (LRMN), Founding Member of the UK - Israel Science Council, Scientific Advisory Board of the UK Cell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell Netwcell and gene therapies including; Founder and CEO of the London Regenerative Medicine Network (LRMN), Founding Member of the UK - Israel Science Council, Scientific Advisory Board of the UK Cell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell Netwgene therapies including; Founder and CEO of the London Regenerative Medicine Network (LRMN), Founding Member of the UK - Israel Science Council, Scientific Advisory Board of the UK Cell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell NetwCell and Gene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell NetwGene Therapy Catapult, Strategic Advisory Board of the Canadian Centre for the Commercialization of Regenerative Medicine (CCRM), and Scientific Advisory Board of the Canadian Stem Cell NetwCell Network.

Prior to that, Dr. Matushansky was at Novartis where he was Global Head for Clinical and Scientific Development at its Gene & Cell Therapy Unit as well as a Global Clinical Program Lead within Novartis» Oncology Translational Medicine Unit.